Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.58 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | CPA1 | P15085 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849821 | 1.00 | PPARG (0.58) | PPARGPPARAITGB1ITGA4ITGB7 | |
| SCHEMBL2847851 | 1.00 | PPARG (0.58) | PPARGPPARAITGB1ITGA4ITGB7 | |
| SCHEMBL2847849 | 1.00 | PPARG (0.58) | PPARGPPARAITGB1ITGA4ITGB7 | |
| SCHEMBL2856237 | 0.92 | PPARG (0.61) | PPARG | |
| SCHEMBL2859548 | 0.92 | PPARG (0.61) | PPARG | |
| SCHEMBL6158614 | 0.84 | ITGB1 (0.47) | ITGB1ITGA4ITGB7MMEACE | |
| SCHEMBL6156042 | 0.82 | ITGB3 (0.46) | ITGB1ITGA4ITGB7MMEACE | |
| SCHEMBL2853135 | 0.81 | ACE (0.56) | PPARGPPARAITGB1ITGA4ITGB7 | |
| SCHEMBL3439147 | 0.81 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL2853142 | 0.81 | ACE (0.56) | PPARGPPARAITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807669-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | claimed |
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-05 | — | — | US | claimed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | claimed |
| US-7807669-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| EP-1575911-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-01-13 | — | — | EP | disclosed |
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-05 | — | — | US | disclosed |
| US-7452878-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | disclosed |
| EP-1575911-A2 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004046091-A2 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885ITGB1 3957/4885 |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885ITGB1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.